Welcome to our dedicated page for Icecure Medical Ltd. news (Ticker: ICCM), a resource for investors and traders seeking the latest updates and insights on Icecure Medical Ltd. stock.
Overview of IceCure Medical Ltd.
IceCure Medical Ltd (ICCM) is a commercial-stage medical device company specializing in liquid nitrogen-based cryoablation systems. The company develops and markets minimally invasive technologies designed to destroy tumors through cryoablation, offering a viable alternative to traditional surgical tumor removal. By harnessing the power of liquid nitrogen, IceCure's systems create large lethal zones within tumors, providing a safe and efficient method for treating a variety of conditions including breast, kidney, bone, and lung cancers. This technology is proving essential in the shift toward less invasive medical treatments, marking significant advancements in the field of oncology.
Core Business and Technology
The primary focus of IceCure is on research, development, and commercialization of cryoablation therapy systems. Their flagship product leverages advanced cryogenic engineering to deliver precise ablation of both benign and malignant tumors. Using state-of-the-art cryoprobes and proprietary liquid nitrogen systems, IceCure offers a minimally invasive alternative that reduces surgical risks, shortens recovery times, and minimizes patient discomfort compared to conventional surgical methods. This robust technological foundation is supported by a significant portfolio of patents and continued innovation, underscoring the company’s commitment to remaining at the forefront of cryosurgical treatments.
Market Position and Industry Significance
Within the medical device market, IceCure occupies a unique niche by focusing exclusively on cryoablation. The company’s solutions are positioned as important tools for solid tumor treatments in multiple clinical settings, including hospitals and office-based procedures. With a strong emphasis on clinical research, IceCure’s technologies have been validated through extensive studies and trials, further enhancing their credibility among medical professionals. The company’s achievements, such as receiving key regulatory approvals and positive evaluations from expert panels, also contribute to its recognized position within the competitive landscape of minimally invasive surgery technologies.
Clinical Evidence and Research
IceCure’s commitment to rigorous clinical validation is evident in its comprehensive body of research. Multiple studies and clinical trials have demonstrated that cryoablation using IceCure’s systems achieves outcomes comparable to standard surgical interventions but with significantly lower rates of complications and shorter recovery periods. The company’s approach has garnered attention at major medical conferences, and independent studies consistently highlight the efficacy and safety of their methodology. This research-based approach not only drives clinical adoption but also reinforces the trustworthiness and expertise of IceCure’s technology in the field of oncologic treatment.
Innovation and Regulatory Milestones
Innovation is a core driver for IceCure, which continually refines its technology and expands its intellectual property portfolio. With multiple patents already granted and more under review, the company remains dedicated to advancing its cryoablation systems to meet an expanding range of clinical needs. Strategic regulatory approvals across key global markets such as the U.S., Europe, China, and others attest to the quality and reliability of its products. These achievements reflect IceCure’s commitment to improving patient outcomes and strengthening its market presence in the competitive field of medical devices.
Application and Patient Benefits
IceCure’s cryoablation systems are distinguished by their ability to provide effective tumor destruction with minimal patient discomfort. The technology not only reduces the pain and risks associated with conventional surgery but also facilitates faster recovery times, allowing patients to resume their normal lives more quickly. By offering an office-based, easy-to-perform procedure, IceCure is expanding access to advanced treatment options and paving the way for broader acceptance of minimally invasive therapies in oncologic care.
Conclusion
IceCure Medical Ltd stands as a notable innovator in the field of cryoablation therapy. With a deep commitment to clinical research, technological innovation, and regulatory excellence, the company provides a compelling alternative to traditional surgery for tumor management. Its focused approach and comprehensive product portfolio underscore its significance in the broader context of minimally invasive medical treatments, cementing its role as a trusted entity among healthcare professionals and stakeholders worldwide.
IceCure Medical (ICCM) reported its 2024 financial results, highlighting a 42% growth in ProSense® cryoablation sales in North America. Total revenue increased to $3.29M from $3.23M in 2023, with product sales reaching $3.19M. Gross profit grew 12% to $1.45M with a 44% margin.
The company awaits FDA marketing authorization for ProSense® in early-stage low-risk breast cancer with endocrine therapy, following a favorable Advisory Panel decision in November 2024. ProSense® demonstrated increased adoption globally, with 33 peer-reviewed studies published in 2024.
Financial highlights include a 14% decrease in R&D expenses to $7.10M, a 42% increase in sales and marketing expenses to $6.30M, and a 10% decrease in general administrative expenses to $3.76M. The company reported a net loss of $15.32M ($0.30 per share) and held cash and equivalents of $7.6M as of December 2024.
IceCure Medical (NASDAQ: ICCM) has presented interim results from its ICESECRET study on ProSense® cryoablation for small renal masses at the European Association of Urology Conference in Madrid. The study demonstrated an 88.7% recurrence-free rate in patients with tumors ≤3 cm at a mean follow-up of 3.4 years.
The study evaluated 111 patients with a mean age of 69, of whom 84.2% had comorbidities. Safety results showed 17 mild adverse events, 3 moderate events, and 1 severe complication. The data supports cryoablation as a viable alternative for patients ineligible for kidney-preserving surgery, particularly for tumors ≤3 cm.
ProSense®, which uses liquid nitrogen-based cryoablation technology to destroy tumors by freezing, is currently approved for benign and malignant kidney tumors in the U.S., Europe, and other countries.
IceCure Medical (Nasdaq: ICCM), a developer of minimally-invasive cryoablation technology for tumor treatment, has scheduled its 2024 full year financial and operational results announcement for March 27, 2025. The company will release its results before the Nasdaq market opens, followed by a conference call at 10:00 AM EDT.
The conference call will be accessible via US dial-in (1-888-407-2553) and International dial-in (+972-3-918-0696). A live webcast will be available, with a recording subsequently posted on the company's investor relations website.
IceCure Medical (Nasdaq: ICCM) provided an update on its FDA marketing authorization timeline for ProSense® cryoablation system in early-stage breast cancer treatment. The company now expects the FDA's decision after Q1 2025, extending beyond the initial timeline.
The FDA process has involved extensive stakeholder engagement due to the product's novelty and breast cancer's public health significance. In November 2024, an FDA Medical Device Advisory Committee Panel, comprising breast surgeons, interventional radiologists, oncologists, and patient representatives, voted favorably on ProSense®'s benefit-risk profile for treating early-stage low-risk breast cancer with endocrine therapy.
ProSense® uses minimally-invasive cryoablation technology that destroys tumors by freezing, offering an alternative to surgical tumor removal. The company continues to work closely with the FDA towards a De Novo marketing authorization decision.
IceCure Medical (NASDAQ: ICCM) showcased its ProSense® cryoablation technology at the 19th Annual St. Gallen Breast Cancer Conference, with six peer-reviewed studies presented and to be published in The Breast journal. The studies demonstrate ProSense®'s efficacy in treating breast cancer through tumor freezing.
Key findings include the ICE3 trial showing a 3.61% recurrence rate at 5 years (7/194 patients), with patients receiving endocrine therapy showing a 3.22% recurrence rate. An independent study in Hong Kong successfully expanded treatment to include triple negative breast cancer and younger patients.
The THERMAC trial compared different ablation methods, with ProSense® achieving 94% complete ablation rate and 0% adverse events, outperforming other techniques. Additional studies demonstrated success in treating inoperable patients, with 81.7% complete tumoral necrosis in 60 treated tumors, and showed particular effectiveness in luminal cancers up to 2.5cm.
IceCure Medical (Nasdaq: ICCM) has received a Notice of Allowance from China for its novel 'Cryogenic System Connector' invention, completing patent protection in major global markets including the U.S., Europe, and Japan. The company, which develops minimally-invasive cryoablation technology for tumor destruction, has created an innovative cryogenic pump with several key features:
- Submersible in liquid nitrogen (LN2)
- Operates in a closed circuit
- Enables cryoprobe temperature control
- Improves cooling rate during procedures
- Designed for multiple or longer procedures without LN2 refills
This technological advancement allows IceCure to develop a new generation of compact cryoablation systems and expand their product portfolio to include thinner cryoprobes and catheters. The company currently holds over 50 granted patents for cryoablation systems and cryoprobes.
IceCure Medical (NASDAQ: ICCM) announced significant findings from an independent study published in Gland Surgery, comparing patient satisfaction between their ProSense® cryoablation technology and traditional breast-conserving therapy (BCT) for breast cancer treatment.
The study, conducted at Kameda Medical Center in Japan, revealed that patients who underwent cryoablation reported significantly higher satisfaction scores (71.0±18.6) compared to BCT patients (56.3±16.5), with mean follow-up periods of 4.2 and 4.0 years respectively. The research included 147 Asian female breast cancer patients, with 76 meeting the final analysis criteria (35 cryoablation, 41 BCT).
The study utilized the BREAST-Q questionnaire to assess health-related quality of life and satisfaction. Researchers attributed the higher satisfaction in cryoablation patients to the preservation of breast volume and symmetry, as the procedure doesn't require tissue excision. This data supports the ongoing trend toward de-escalation of breast cancer treatment from surgical to nonsurgical options in Japan.
IceCure Medical (Nasdaq: ICCM) has submitted a regulatory approval filing to Israel's Ministry of Health for its next-generation XSense™ System and CryoProbes. The application covers multiple indications already approved for ProSense®, including general surgery, dermatology, neurology, thoracic surgery, ENT, gynecology, oncology, proctology, and urology.
The company has already secured FDA marketing authorization for the XSense™ System. The filing aligns with growing trends in surgical de-escalation and increasing adoption of minimally invasive cryoablation procedures. The global minimally invasive surgery market is projected to grow at a 17% CAGR between 2022-2029, reaching $174 billion by 2029.
IceCure Medical (NASDAQ: ICCM) showcased its ProSense® cryoablation technology at the 2025 Society of Interventional Oncology Annual Meeting in Las Vegas. Two independent studies demonstrated ProSense®'s safety and efficacy in breast cancer, with one study from the Netherlands winning the 'Highest Scoring Abstract' award. This study concluded that cryoablation was the only thermal ablative technique warranting a Phase 3 trial versus surgery.
The company sponsored a Breast Cryoablation Mini Master Class, featuring leading experts in the field. The FDA's decision on ProSense® market authorization for early-stage breast cancer is expected in Q1 2025. The Dutch study showed 94% complete ablation rate for cryoablation with 0% adverse events, while a Romanian study reported 100% technical success for tumors ≤35 mm with high physician and patient satisfaction.
IceCure Medical (Nasdaq: ICCM) has submitted a regulatory filing to China's National Medical Products Administration (NMPA) for its ProSense® Cryoablation System. The company, which already has approval for its IceSense3 system in China, is seeking to expand its presence in the Chinese market.
The ProSense® application includes expanded capabilities compared to IceSense3, featuring five different cryoprobes with varying specifications and introducers for better tissue accessibility. The system's indicated uses cover multiple medical fields including general surgery, breast tissue, dermatology, thoracic surgery, gynecology, oncology, proctology, and urology.
FAQ
What is the current stock price of Icecure Medical Ltd. (ICCM)?
What is the market cap of Icecure Medical Ltd. (ICCM)?
What is the core business of IceCure Medical Ltd?
How does cryoablation technology work?
Which clinical indications are addressed by IceCure’s products?
What sets IceCure’s technology apart from traditional surgical methods?
How does IceCure validate the efficacy of its cryoablation systems?
In what markets are IceCure’s products available?
What role does intellectual property play in IceCure’s strategy?
What benefits do patients experience with IceCure’s cryoablation treatment?
